Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/soej.12494 http://scihub22266oqcxt.onion/10.1002/soej.12494 33821046!8012986!33821046     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       South+Econ+J 2021 ; 87 (4): 1210-1228 Nephropedia Template TP {{tp|p=33821046|t=2021. The FDA and the COVID-19: A political economy perspective |pdf=|usr=}}{{33821046}} gab.com Text The FDA and the COVID-19: A political economy perspective JO: South Econ J http://www.kidney.de/pget.php?&tw=1&pmid=33821046 #FOAvip This article utilizes a political economy framework to examine how FDA regulations impacted the U.S. healthcare sector's ability to address COVID-19. I specifically examine the developing COVID-19 testing, the approval of the medication remdesivir, and COVID-19 vaccines. By examining periods before and after the FDA issued Emergency Use Authorizations (EUAs), my analysis finds that the FDA's regulations enacted before the COVID-19 pandemic began strongly restricted clinician and patient access to COVID-19 testing, remdesivir treatment, and approving vaccines. After the FDA issued EUAs, the healthcare sector quickly adopted COVID-19 testing and remdesivir with little evidence of negative consequences. These findings contribute to the economics literature examining the FDA and contemporary COVID-19 policy research. Twit Text FOAVip The FDA and the COVID-19: A political economy perspective ????South Econ J http://www.kidney.de/pget.php?&tw=1&pmid=33821046 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33821046 #FOAvip English Wikipedia <ref>{{Cite pmid|33821046}}</ref> The FDA and the COVID-19: A political economy perspective #MMPMID33821046 March RJ South Econ J 2021[Apr]; 87 (4): 1210-1228 PMID33821046show ga This article utilizes a political economy framework to examine how FDA regulations impacted the U.S. healthcare sector's ability to address COVID-19. I specifically examine the developing COVID-19 testing, the approval of the medication remdesivir, and COVID-19 vaccines. By examining periods before and after the FDA issued Emergency Use Authorizations (EUAs), my analysis finds that the FDA's regulations enacted before the COVID-19 pandemic began strongly restricted clinician and patient access to COVID-19 testing, remdesivir treatment, and approving vaccines. After the FDA issued EUAs, the healthcare sector quickly adopted COVID-19 testing and remdesivir with little evidence of negative consequences. These findings contribute to the economics literature examining the FDA and contemporary COVID-19 policy research. äThe FDA and the COVID-19: A political economy perspective (epmc).pdf DeepDyve Pubget Overpricing